Lv1
82 积分 2022-01-26 加入
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
1天前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
14天前
已完结
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
15天前
已完结
Ovarian ablation for early breast cancer
15天前
已关闭
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
16天前
已完结
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
17天前
已完结
Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
18天前
已关闭
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
19天前
已完结
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
19天前
已完结
Predicting MammaPrint Recurrence Risk from Breast Cancer Pathological Images Using a Weakly Supervised Transformer
23天前
已完结
皖公网安备34019202002308
